Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults

被引:31
作者
Oguogho, A
Lupattelli, G
Palumbo, B
Sinzinger, H
机构
[1] Wilhelm Auerswald Atherosclerosis Res Grp ASF, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Nucl Med, A-1010 Vienna, Austria
[3] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy
[4] Univ Perugia, Inst Nucl Med, I-06100 Perugia, Italy
来源
VASA-JOURNAL OF VASCULAR DISEASES | 2000年 / 29卷 / 02期
关键词
cigarette smoking; oxidation injury; isoprostanes; 8-epi-prostaglandin F-2 alpha;
D O I
10.1024/0301-1526.29.2.103
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Isoprostanes and in particular 8-epi-PGF(2 alpha) have been claimed as a useful measure for in-vivo oxidation injury. While smokers show elevated 8-epi-PGF(2 alpha) the behaviour during quitting smoking is unknown. Methods and results: We determined 8-epi-PGF(2 alpha) in 7 healthy adults ready to quit smoking in plasma, serum and urine by means of an enzyme immunoassay, after extraction and purification before quitting smoking and during a follow-up period of 4 weeks. After quitting smoking, 8-epi-PGF(2 alpha) shows a rapid decline within a few days almost completely normalizing with in 4 weeks. Conclusion: The cigarette-smoking associated in-vivo oxidation injury almost completely disappears within 4 weeks of quitting smoking.
引用
收藏
页码:103 / 105
页数:3
相关论文
共 21 条
[1]  
Aghajanian AA, 1997, VASA-J VASCULAR DIS, V26, P65
[2]   Isoprostanes - Prostaglandin-like compounds formed in vivo independently of cyclooxygenase - Use as clinical indicators of oxidant damage [J].
Awad, JA ;
Roberts, JL ;
Burk, RF ;
Morrow, JD .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1996, 25 (02) :409-&
[3]   VASCULAR SMOOTH-MUSCLE ACTIONS AND RECEPTOR INTERACTIONS OF 8-ISO-PROSTAGLANDIN-E2, AND E2-ISOPROSTANE [J].
FUKUNAGA, M ;
TAKAHASHI, K ;
BADR, KF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 195 (02) :507-515
[4]  
FUKUNAGA M, 1995, J CARDIOVASC PHAR S3, V26, P51
[5]   FORMATION OF PGF(2)-ISOPROSTANES DURING THE OXIDATIVE MODIFICATION OF LOW-DENSITY-LIPOPROTEIN [J].
GOPAUL, NK ;
NOUROOZZADEH, J ;
MALLET, AI ;
ANGGARD, EE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (01) :338-343
[6]   INTERACTIONS OF THE MAJOR RISK-FACTORS FOR CORONARY HEART-DISEASE [J].
GOTTO, AM .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (2A) :48-55
[7]   Coronary artery constriction by the isoprostane 8-epi prostaglandin F-2 alpha [J].
Kromer, BM ;
Tippins, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (06) :1276-1280
[8]   The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets [J].
Leitinger, N ;
Blazek, I ;
Sinzinger, H .
THROMBOSIS RESEARCH, 1997, 86 (04) :337-342
[9]   INCREASE IN CIRCULATING PRODUCTS OF LIPID-PEROXIDATION (F-2-ISOPROSTANES) IN SMOKERS - SMOKING AS A CAUSE OF OXIDATIVE DAMAGE [J].
MORROW, JD ;
FREI, B ;
LONGMIRE, AW ;
GAZIANO, JM ;
LYNCH, SM ;
SHYR, Y ;
STRAUSS, WE ;
OATES, JA ;
ROBERTS, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (18) :1198-1203
[10]   The isoprostanes - Current knowledge and directions for future research [J].
Morrow, JD ;
Roberts, LJ .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (01) :1-9